Dr. Hoffman-Censits

Jean Hoffman-Censits, MD

Contact Dr. Hoffman-Censits

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Recurrent renal cell carcinoma presenting as a solitary left ventricular mass
  2. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
  3. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: Patient selection and special considerations
  4. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature
  5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  6. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
  7. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer
  8. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  9. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  10. Combination immunotherapy in genitourinary malignancies
  11. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma
  12. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
  13. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
  14. Systemic chemotherapy for upper tract urothelial cancer
  15. Perioperative and Maintenance Therapy after First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma
  16. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  17. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
  18. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity
  19. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
  20. Practical guide to the use of enzalutamide